Today Lilly announced they would be selling a generic version of their most popular short acting insulin Humalog. Per a press release;
“Reinforcing our commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Company (NYSE: LLY) today announced we will introduce a lower-priced version of Humalog® (insulin lispro injection 100 units/mL) in the United States -- providing people with diabetes an insulin option that will have a list price 50 percent lower than the current Humalog list price.”
The release goes onto state;
“The lower-priced version will be called Insulin Lispro—the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.